KR100478467B1 - 피라졸-3-온 유도체, 그 제조방법 및 약제학적 조성물 - Google Patents

피라졸-3-온 유도체, 그 제조방법 및 약제학적 조성물 Download PDF

Info

Publication number
KR100478467B1
KR100478467B1 KR10-2002-0035411A KR20020035411A KR100478467B1 KR 100478467 B1 KR100478467 B1 KR 100478467B1 KR 20020035411 A KR20020035411 A KR 20020035411A KR 100478467 B1 KR100478467 B1 KR 100478467B1
Authority
KR
South Korea
Prior art keywords
formula
pyrazol
alkyl
methanesulfonylphenyl
derivative
Prior art date
Application number
KR10-2002-0035411A
Other languages
English (en)
Korean (ko)
Other versions
KR20040000221A (ko
Inventor
조일환
노지영
박상욱
유형철
임지웅
김종훈
채명윤
김달현
정성학
박현정
김영훈
민인기
Original Assignee
씨제이 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨제이 주식회사 filed Critical 씨제이 주식회사
Priority to KR10-2002-0035411A priority Critical patent/KR100478467B1/ko
Priority to US10/461,978 priority patent/US6689805B2/en
Priority to JP2004515206A priority patent/JP4257292B2/ja
Priority to EP03760957A priority patent/EP1515952A4/de
Priority to CN038145782A priority patent/CN1662507A/zh
Priority to PCT/KR2003/001172 priority patent/WO2004000206A2/en
Priority to AU2003232684A priority patent/AU2003232684A1/en
Publication of KR20040000221A publication Critical patent/KR20040000221A/ko
Application granted granted Critical
Publication of KR100478467B1 publication Critical patent/KR100478467B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR10-2002-0035411A 2002-06-24 2002-06-24 피라졸-3-온 유도체, 그 제조방법 및 약제학적 조성물 KR100478467B1 (ko)

Priority Applications (7)

Application Number Priority Date Filing Date Title
KR10-2002-0035411A KR100478467B1 (ko) 2002-06-24 2002-06-24 피라졸-3-온 유도체, 그 제조방법 및 약제학적 조성물
US10/461,978 US6689805B2 (en) 2002-06-24 2003-06-13 Pyrazole-3-one derivative, method for preparing the same, and pharmaceutical composition containing the same
JP2004515206A JP4257292B2 (ja) 2002-06-24 2003-06-16 ピラゾール−３−オン誘導体、その調製方法、及びそれを含む薬学的組成物
EP03760957A EP1515952A4 (de) 2002-06-24 2003-06-16 Pyrazol-3-one-derivat, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zusammensetzung
CN038145782A CN1662507A (zh) 2002-06-24 2003-06-16 吡唑－3－酮衍生物,它的制备方法和含有它的药物组合物
PCT/KR2003/001172 WO2004000206A2 (en) 2002-06-24 2003-06-16 Pyrazole-3-one derivative, method for preparing the same, and pharmaceutical composition containing the same
AU2003232684A AU2003232684A1 (en) 2002-06-24 2003-06-16 Pyrazole-3-one derivative, method for preparing the same, and pharmaceutical composition containing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-2002-0035411A KR100478467B1 (ko) 2002-06-24 2002-06-24 피라졸-3-온 유도체, 그 제조방법 및 약제학적 조성물

Publications (2)

Publication Number Publication Date
KR20040000221A KR20040000221A (ko) 2004-01-03
KR100478467B1 true KR100478467B1 (ko) 2005-03-23

Family

ID=29774937

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2002-0035411A KR100478467B1 (ko) 2002-06-24 2002-06-24 피라졸-3-온 유도체, 그 제조방법 및 약제학적 조성물

Country Status (7)

Country Link
US (1) US6689805B2 (de)
EP (1) EP1515952A4 (de)
JP (1) JP4257292B2 (de)
KR (1) KR100478467B1 (de)
CN (1) CN1662507A (de)
AU (1) AU2003232684A1 (de)
WO (1) WO2004000206A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
CN103601681B (zh) * 2013-11-29 2015-12-09 郑州大学 含环外双键结构单元的3,5-吡唑二酮衍生物及其制备方法和用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57176963A (en) * 1981-04-25 1982-10-30 Otsuka Chem Co Ltd Preparation of 1,3-di-substituted-5-pyrazolone derivative
JPS62108814A (ja) * 1985-11-07 1987-05-20 Mitsubishi Chem Ind Ltd 過酸化脂質生成抑制剤
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5492799A (en) * 1992-12-23 1996-02-20 Eastman Kodak Company Azopyrazolone masking couplers
WO2001016138A1 (en) * 1999-08-27 2001-03-08 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors
JP2001206876A (ja) * 1999-12-03 2001-07-31 Pfizer Prod Inc 抗炎症剤／鎮痛剤としてのアセチレン誘導体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6456664A (en) * 1987-08-27 1989-03-03 Nissan Chemical Ind Ltd Pyrazole derivative and insect pest controlling agent
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
KR19990080440A (ko) * 1998-04-17 1999-11-05 성재갑 신규한 피라졸 유도체
US6316466B1 (en) * 1998-05-05 2001-11-13 Syntex (U.S.A.) Llc Pyrazole derivatives P-38 MAP kinase inhibitors
JP2000239555A (ja) * 1999-02-16 2000-09-05 Chemiprokasei Kaisha Ltd アリリデンビス−ピラゾロン誘導体の用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57176963A (en) * 1981-04-25 1982-10-30 Otsuka Chem Co Ltd Preparation of 1,3-di-substituted-5-pyrazolone derivative
JPS62108814A (ja) * 1985-11-07 1987-05-20 Mitsubishi Chem Ind Ltd 過酸化脂質生成抑制剤
US5492799A (en) * 1992-12-23 1996-02-20 Eastman Kodak Company Azopyrazolone masking couplers
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
WO2001016138A1 (en) * 1999-08-27 2001-03-08 Abbott Laboratories Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors
JP2001206876A (ja) * 1999-12-03 2001-07-31 Pfizer Prod Inc 抗炎症剤／鎮痛剤としてのアセチレン誘導体

Also Published As

Publication number Publication date
CN1662507A (zh) 2005-08-31
US20040002532A1 (en) 2004-01-01
WO2004000206A2 (en) 2003-12-31
US6689805B2 (en) 2004-02-10
KR20040000221A (ko) 2004-01-03
EP1515952A2 (de) 2005-03-23
JP2006504639A (ja) 2006-02-09
EP1515952A4 (de) 2007-06-06
AU2003232684A1 (en) 2004-01-06
JP4257292B2 (ja) 2009-04-22
WO2004000206A3 (en) 2004-03-25
AU2003232684A8 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
KR100478467B1 (ko) 피라졸-3-온 유도체, 그 제조방법 및 약제학적 조성물
KR100484525B1 (ko) 이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
KR100470075B1 (ko) 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
KR100465455B1 (ko) 2-티옥소티아졸 유도체, 그 제조방법 및 약제학적 조성물
KR100804827B1 (ko) 티아졸리딘-4-온 유도체, 그 제조방법 및 약제학적 조성물
KR100470076B1 (ko) 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
JP4348301B2 (ja) １，２，４−トリアゾール誘導体、その製造方法及びそれを含む薬学的組成物
KR100641280B1 (ko) [1,2]디티올-3-티온 유도체, 그 제조방법 및 약제학적조성물
KR100484526B1 (ko) 티온 유도체, 그 제조방법 및 약제학적 조성물
KR100596370B1 (ko) 이소옥사졸 유도체, 그 제조방법 및 약제학적 조성물
KR100576343B1 (ko) 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
KR100576337B1 (ko) 피리다진-4-온 유도체, 그 제조방법 및 약제학적 조성물
KR100576338B1 (ko) 피리다진-4-온 유도체, 그 제조방법 및 약제학적 조성물
KR20050052618A (ko) 피리다진-4-온 유도체, 그 제조방법 및 약제학적 조성물

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
J201 Request for trial against refusal decision
J121 Written withdrawal of request for trial
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121218

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20131128

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee